Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study

British Journal of Psychiatry

Volumn 187, Issue AUG., 2005, Pages 137-142

  Park, Sylvia ^a,b   Ross Degnan, Dennis ^a   Adams, Alyce S ^a   Sabin, James ^a   Kanavos, Panos ^c   Soumerai, Stephen B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Korea Health Industry Development Institute   (South Korea)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; SCHIZOPHRENIA;

ADULT; AGE FACTORS; AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CHLORPROMAZINE; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; FAMILY PRACTICE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS;

EID: 23744432102     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.187.2.137     Document Type: Article

References (22)

1. Barak, Y., Shamir, E. & Weizman, R. (2002) Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. Journal of Clinical Psychopharmacology, 22, 115-120.
2. Bobes, J., Gibert, J., Ciudad, A., et al (2003) Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 473-481.
3. Bouchard, R. H., Merette, C., Pourcher, E., et al (2000) Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. Journal of Clinical Psychopharmacology, 20, 295-304.
4. Buckley, P. F., Miller, A., Chiles, J. A., et al (1999) Implementing effectiveness research and improving care for schizophrenia in real-world settings. American Journal of Managed Care, 5, SP47-56.
5. Coley, K. C., Carter, C. S., DaPos, S.V., et al (1999) Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Journal of Clinical Psychiatry, 60, 850-856.
6. Costa e Silva, J. A., Alvarez, N., Mazzotti, G., et al (2001) Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. Journal of Clinical Psychopharmacology, 21, 375-381.
7. Freedman, R. (2003) Schizophrenia. New England Journal of Medicine, 349, 1738-1749.
8. Inada, T., Yagi, G. & Miura, S. (2001) Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia Research, 57, 227-238.
9. Knapp, M. (1997) Costs of schizophrenia. British Journal of Psychiatry, 171, 509-518.
10. Lang, F. H., Johnstone, E. C. & Murray, G. D. (1997) Service provision for people with schizophrenia. II. Role of the general practitioner. British Journal of Psychiatry, 171, 165-168.
11. Lindstrom, E. & Bingefors, K. (2000) Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics, 18, 106-124.
12. Montes, J. M., Ciudad, A., Gascon, J., et al (2003) Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 667-674.
13. Ritchie, C. W., Chiu, E., Harrigan, S., et al (2003) The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. International Journal of Geriatric Psychiatry, 18, 432-440.
14. SAS Institute (2000a) SAS/ETS User's Guide, Version 8. Cary, NC: SAS Institute.
15. SAS Institute (2000b) SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute.
16. Soholm, B. & Lublin, H. (2003) Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A minor study. Acta Psychiatrica Scandinavica, 107, 344-350.
17. Soumerai, S. B. (2004) Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs, 23, 135-146.
18. Tamminga, C. (2003) Similarities and differences among antipsychotics. Journal of Clinical Psychiatry, 64, 7-10.
19. Tran, P. V., Hamilton, S. H., Kuntz, A. J., et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407-418.
20. Tran, P.V., Tollefson, G. D., Sanger, T. M., et al (1999) Olanzapine versus haloperidol in the treatment of schizoaffective disorder: Acute and long-term therapy. British Journal of Psychiatry, 174, 15-22.
21. Wagner, A. K., Soumerai, S. B., Zhang, F., et al (2002) Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics, 27, 299-309.
22. Walley, T. & Mantgani, A. (1997) The UK General Practice Research Database. Lancet, 350, 1097-1099.